Hyresintäkterna steg med hela 72% till 15,6 meur och förvaltningsresultat ökade med nästan 50% till ...
NOI +75% y-o-y and -0.7% vs ABGSCe Value uplift 2.1% q-o-q, net LTV at 48.
Redeye comments on Kardium's 1-year study results for its CHS-coated Globe system.
Redeye endorses CLS’s FDA submission to include 1.5 Tesla MRI guidance to the Prism system.
Redeye leaves its initial comments on Nanologica following the recent news that Flerie Invest has pa...
Fastpartners hyresintäkter och driftnetto minskade något för det första kvartalet drivet av avyttrin...
The company’s reported EBITDA was EUR 21m (Nordea est.
Redeye comments on Nitro Games' Q1 2025 report, which came in roughly in line with expectations.
Q1: -18% org. sales growth, -77% adj. EBITA growth, solid cash flow '25e-'27e adj.
Alternative MRI contrast agent for frail cancer patients Ph 3 finished and ready for FDA filing Init...
The start of 2025 was weaker than market consensus (LSEG) expected.
Redeye has updated its estimates and valuation for Sleep Cycle following the Q1 2025 report, which w...
AVTECH showed solid growth at 33% y/y, meeting Redeye Research estimates (RRe), driven by new contra...
Redeye updates its estimates and valuation following the Q1 2025 report from Safeture.
Redeye is only making some minor adjustments to our forecasts and valuation on the back of Q1 number...
Redeye remains confident on the long-term case despite a major air pocket in the first quarter.
Redeye remains optimistic about Insplorion’s prospects to establish the company as a provider of hig...
Redeye retains its positive view of Vertiseit following a Q1 report where FX and a higher headcount ...
Cost initiatives a success in FWMT... ...and Scandpower continues to excel High competition and pric...
Limited estimate revisions Promising outlook for international expansion Maintain fair value range o...